Evolving Treatment for Relapsed/Refractory Multiple Myeloma: New Therapeutic Targets in This Challenging Disease 

Pre-test

Of the bispecific antibodies that are currently US Food and Drug Administration–approved for the treatment of relapsed/refractory multiple myeloma, which of them targets the GPRC5D receptor on myeloma cells? 

An 80-year-old woman was diagnosed with multiple myeloma 15 years ago. In the past, she has been treated with bortezomib-lenalidomide-dexamethasone followed by autologous stem cell transplant (ASCT) and lenalidomide as first-line treatment. She then received daratumumab-carfilzomib and dexamethasone as second-line treatment and relapsed after 13 months. As third-line treatment elotuzumab-pomalidomide and dexamethasone were given to her but her disease progressed. Next, she received selinexor and dexamethasone as fourth-line treatment and has now relapsed after 22 months. Finally, she underwent chimeric antigen receptor T-cell (CAR-T) therapy with ciltacabtageneautoleucel but her disease relapsed. What would be your next recommendation?